Company: IOBT
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0000950170-25-058699
Chunk: 37

Company: IO Biotech, Inc.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 37
---
 | Position(s)                          |
| Mai-Britt Zocca, Ph.D. |     |  57 |     | Chief Executive Officer and Director |
| Qasim Ahmad, M.D.      |     |  54 |     | Chief Medical Officer                |
| Amy Sullivan, M.B.A.   |     |  55 |     | Chief Financial Officer              |
| Devin W. Smith         |     |  57 |     | General Counsel                      |

Mai-Britt Zocca, Ph.D. – Biographical information for Dr. Zocca is included above with the director biographies under the caption “Information Regarding Nominees and Continuing Directors – Continuing Directors – Class III Directors.” Qasim Ahmad, M.D. – Dr. Ahmad has served as our Chief Medical Officer since July 2023. Dr. Ahmad was previously employed by Novartis AG, where he most recently served as Senior Vice President, US Head of Clinical Development & Medical Affairs, for the Novartis Oncology business unit. A trained internist and clinical oncologist, he brings over two decades of successful strategic clinical development, medical affairs, and marketing authorization expertise to the Company. Dr. Ahmad received an MS in Global Health Policy Management from the London School of Hygiene and Tropical Medicine, University of London, United Kingdom, a Master of Pharmaceutical Medicine from University of Surrey, UK, a Master of Clinical Oncology from the University of Birmingham, UK, and his medical degree from the University of Punjab, Lahore, Pakistan. Amy Sullivan, M.B.A. –Ms. Sullivan joined the Company from TABA, BV, a special purpose acquisition company, where she served as chief financial officer beginning in May 2021. Prior to her time with TABA, Ms. Sullivan was chief strategy office for Euronext-listed Kiadis Pharma B.V., a biopharmaceutical company from January 2019 until May 2021, where she was responsible for all aspects of fundraising and capital formation strategy, repositioning the company after a clinical failure, and played a critical role in the company’s sale to Sanofi. Prior to Kiadis, Ms. Sullivan served Keryx Biopharmaceuticals, Inc. from April 2014 to December 2018 where she was senior vice president of corporate affairs, responsible for all aspects of investor relations, corporate communication, and public affairs, during a period of high growth, commercialization of the company’s first FDA-approved medicine and, ultimately